Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic.
Nevro is proud to continue our longstanding commitment to investing in the field of neuromodulation and expanding our growing body of clinical evidence, said D. Keith Grossman, Chairman, CEO and President of Nevro. We are excited for Dr. Petersen and Dr. Kapural to share the significant data from the SENZA-PDN and the SENZA-NSRBP trials at NANS, reflecting our commitment to helping physicians treat underserved patient populations suffering from debilitating chronic pain. Additionally, we are pleased the many clinical investigators studying HF10 will have the opportunity to present the results of numerous additional studies we are conducting globally.
Key amongst these presentations will be data for the SENZA-Painful Diabetic Neuropathy (PDN) randomized clinical trial (RCT) and a first look at results from the Non-Surgical Refractory Back Pain (NSRBP) RCT: